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Mutations in the inositol 5-phosphatase OCRL
are responsible for Lowe syndrome, whose
manifestations include mental retardation and
renal Fanconi syndrome. OCRL has been impli-
cated in membrane trafficking, but disease
mechanisms remain unclear. We show that
OCRL visits late-stage, endocytic clathrin-
coated pits and binds the Rab5 effector
APPL1 on peripheral early endosomes. The in-
teraction with APPL1, which is mediated by
the ASH-RhoGAP-like domains of OCRL and
is abolished by disease mutations, provides a
link to protein networks implicated in the re-
absorptive function of the kidney and in the traf-
ficking and signaling of growth factor receptors
in the brain. Crystallographic studies reveal
a role of the ASH-RhoGAP-like domains in posi-
tioning the phosphatase domain at the mem-
brane interface and a clathrin box protruding
from the RhoGAP-like domain. Our results sup-
port a role of OCRL in the early endocytic path-
way, consistent with the predominant localiza-
tion of its preferred substrates, PI(4,5)P2 and
PI(3,4,5)P3, at the cell surface.
INTRODUCTION
Regulated and reversible phosphorylation of the inositol
ring of phosphatidylinositol generates seven ‘‘phospho-
inositides,’’ which play major regulatory roles in cell phys-
iology (Di Paolo and De Camilli, 2006). The human genome
encodes ten inositol 5-phosphatases, i.e., enzymes that
selectively dephosphorylate the 5 position of the inositol
ring (Astle et al., 2006). Mutations in one of them, OCRL,
cause Oculocerebrorenal Syndrome of Lowe, an X-linkedDevelopmendisorder characterized by congenital cataracts, mental
retardation, and renal Fanconi syndrome (Attree et al.,
1992). OCRL mutations were also identified in a subset
of Dent disease patients, a condition that, like Lowe syn-
drome, is associated with loss of low-molecular weight
proteins and electrolytes in the urine (Hoopes et al., 2005).
OCRL has a multidomain structure, with a central 5-
phosphatase domain, whose preferred substrates are
PI(4,5)P2 and PI(3,4,5)P3 (Schmid et al., 2004; Zhang
et al., 1995), followed by a sequence recently defined as
an ASH domain (ASPM, SPD2, Hydin) (Ponting, 2006)
and by a COOH-terminal, catalytically inactive RhoGAP
domain. OCRL is an effector for several Rab proteins
and also binds clathrin and clathrin adaptors (Choudhury
et al., 2005; Hyvola et al., 2006; Ungewickell et al., 2004).
OCRL was initially localized to the Golgi complex
(Dressman et al., 2000; Olivos-Glander et al., 1995), and
it is recruited to membrane ruffles in response to growth
factor stimulation and Rac activation (Faucherre et al.,
2005). More recently, it was also detected on endosomes
and on clathrin-positive intracellular structures, in agree-
ment with its binding to Rab5 and to clathrin, and it was
implicated in membrane trafficking from endosomes to
the Golgi (Choudhury et al., 2005; Hyvola et al., 2006; Un-
gewickell et al., 2004). So far, however, OCRL was not
detected at endocytic clathrin-coated pits, in spite of its
binding in vitro to the clathrin adaptor AP-2 (Ungewickell
et al., 2004).
OCRL is similar to another inositol 5-phosphatase,
INPP5B (also referred to as type II 5-phosphatase). The
two enzymes have primarily been studied in different con-
texts, but they appear to have at least partially overlapping
functions and similar enzymatic properties (Astle et al.,
2006; Jefferson and Majerus, 1995). Like OCRL, INPP5B
interacts with Rab5 and is recruited to plasma membrane
ruffles upon growth factor stimulation (Shin et al., 2005). In
mice, disruption of both genes is lethal, while disruption of
a single gene produces no apparent phenotype (OCRL) or
only a minor phenotype (INPP5B) (Hellsten et al., 2001;
Janne et al., 1998).tal Cell 13, 377–390, September 2007 ª2007 Elsevier Inc. 377
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OCRL in Early Steps of the Endocytic PathwayFigure 1. OCRL and the Early Endocytic Pathway
(A) Immunofluorescence of the intracellular distribution of Myc-tagged OCRL in Cos-7 cells and comparison with the distribution of cotransfected
Xpress-tagged INPP5B.
(B) RFP-OCRL (and RFP-INPP5B) colocalizes with EGFP-Rab5-positive endosomes- but not with EGFP-Rab9-positive organelles.
(C) EGFP-OCRL-positive spots are directly adjacent to endogenous retromer (SNX1) immunoactivity, suggesting budding of the retromer-positive
membrane from OCRL-positive endosomes.
(D) Modular structure of OCRL and INPP5B.
(E) Total internal reflection fluorescence (TIRF) microscopy of Cos-7 cells transfected with EGFP-clathrin light chain together with RFP-OCRL (left
column) or RFP-INPP5B (right column). OCRL, but not INPP5B, colocalizes with a subset of clathrin spots in these single short-exposure (200 ms)
frames.
(F) Percentage of clathrin-coated pits positive for INPP5B or for OCRL during their lifetime.
(G and H) (G) Sequential TIRF microscopy images (8 s intervals) and (H) time course of fluorescence intensity for two clathrin-coated pits from cells
cotransfected with RFP-clathrin and EGFP-OCRL. Note: In (H), fluorescence is measured at a specific position so that both loss of fluorescence and
lateral movement of the fluorescent spot away from such a position result in a loss of signal intensity.378 Developmental Cell 13, 377–390, September 2007 ª2007 Elsevier Inc.
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OCRL in Early Steps of the Endocytic PathwayHow the properties and localization of OCRL relate to
the pathological manifestations of Lowe syndrome re-
mains unclear. The kidney defects observed in Lowe syn-
drome and Dent disease suggest an impairment in the
trafficking of proteins, including receptors, implicated in
reabsorption in the proximal tubule (Lowe, 2005). For ex-
ample, a chloride channel mutation that produces Dent
disease in mouse reduces the surface localization of
megalin, a scavenger receptor (Piwon et al., 2000). Inter-
estingly, decreased levels of the extracellular domain of
megalin were observed in the urine of Lowe syndrome
and Dent disease patients with OCRL mutations (Norden
et al., 2002). Defects in endocytosis and recycling of re-
ceptors in the nervous system could also produce cogni-
tive impairment, another characteristic of Lowe syndrome
patients (Lowe, 2005). However, a molecular link between
OCRL and cell-surface receptors has not been identified
so far.
Here, we show that OCRL is present throughout the
early endocytic pathway, including in endocytic clathrin-
coated pits, and demonstrate a connection between
OCRL and adaptor molecules implicated in the endocytic
trafficking of receptors in the brain and kidney. In addition,
we report the crystallographic structure of the COOH-
terminal region of OCRL, which provides insight into pro-
tein and membrane interactions of this protein.
RESULTS
Localization of OCRL on Early Endosomes
and at Clathrin-Coated Endocytic Pits
Analysis of endogenous OCRL immunoreactivity or of
transfected (EGFP- or Myc-tagged) OCRL expressed in
Cos-7 and HeLa cells revealed, as reported (Choudhury
et al., 2005; Ungewickell et al., 2004), a punctate distribu-
tion throughout the cytoplasm, with an accumulation of
these puncta in the Golgi complex region (Figure 1A)
and some accumulation at peripheral ruffles (Faucherre
et al., 2005). Most peripheral puncta colocalized with
Rab5, an early endosomal protein that interacts with
OCRL (Hyvola et al., 2006), but not with Rab9, a late endo-
somal protein (Figure 1B). Partial colocalization was ob-
served with components (SNX1 and SNX2) of the retromer
(Figure 1C and not shown), a protein complex implicated
in transport from early endosomes to the Golgi complex
(Bonifacino and Rojas, 2006), in agreement with the re-
ported role of OCRL in this transport reaction (Choudhury
et al., 2005; Ungewickell et al., 2004).
Observation of Cos-7 cells coexpressing EGFP-OCRL
and RFP-clathrin light chain by total internal reflection
fluorescence (TIRF) microscopy (Zoncu et al., 2007) re-
vealed that OCRL was also detected transiently at a frac-
tion of endocytic clathrin-coated pits (38%) (Figures 1E
and 1F). Its residence at the pits generally occurred duringDevelopmenthe declining phase of the clathrin fluorescence thought to
reflect internalization of the pit. Often, some OCRL fluo-
rescence persisted and moved away from the location
of the original clathrin spot, suggesting a continued asso-
ciation with the uncoated vesicle (Figures 1G and 1H;
Movie S1, see the Supplemental Data available with this
article online).
An overall similar localization was observed for RFP-
INPP5B (Figures 1A and 1B). However, INPP5B does not
contain the clathrin box and the AP-2-binding motif (Fig-
ure 1D), and it was not detected at endocytic clathrin-
coated pits (Figures 1E and 1F). The interaction of clathrin
heavy chain with OCRL, but not INPP5B, was confirmed by
using GST fusions of OCRL or INPP5B (Figure 1I), or of their
COOH-terminal regions (ASH-RhoGAP-like domains) (not
shown), as baits in pull-downs from rat brain lysate.
OCRL and INPP5B Bind APPL1
The pull-down assays (see above) used to analyze the
clathrin binding of OCRL and INPP5B showed that the
COOH-terminal regions of both proteins, but not GST,
bound a 90 kDa band (Figure 2A). The band was identified
by mass spectrometry, and then western blot, as APPL1
(DIP13alpha) (Figure 2B). Interestingly, APPL1, like OCRL
and INPP5B, is a Rab5 effector and is localized on a sub-
population of peripheral early endosomes (Miaczynska
et al., 2004). Thus, this interaction appeared to be physio-
logically important and was further investigated. Binding
of APPL1 to OCRL/INPP5B is direct because recombinant
APPL1 bound GST fusions of OCRL and INPP5B (Fig-
ure 2C). APPL1 has a close homolog, APPL2. However,
GST pull-downs from extracts of Cos-7 cells expressing
Myc-tagged APPL proteins demonstrated that both
OCRL and INPP5B interact selectively with APPL1
(Figure 2D).
The binding of OCRL/INPP5B to APPL1 was validated
by coprecipitation of HA-tagged OCRL or INPP5B with
Myc-tagged APPL1 from extracts of Cos-7 cells (Figure 2E
and data not shown) and was supported by colocalization
studies. EGFP-APPL1 and endogenous APPL1 immuno-
reactivity colocalized with a subset of peripheral endo-
somes positive for RFP-INPP5B or RFP-OCRL (Figure 2F;
Movies S2 and S3; see Figure 6C and data not shown). In
addition, the recruitment of OCRL and INPP5B to the large
endosomes induced by constitutively active Rab5 (Fig-
ures S2A, S2B, S2F, and S2G) was more robust in cells
also overexpressing APPL1, more so in the case of
INPP5B, which was less efficiently colocalized with
Rab5 alone (Figures S2C–S2E and S2H–S2J).
In contrast to OCRL, APPL1 did not appear to be a res-
ident protein of coated pits, although a relationship be-
tween EGFP-APPL1-positive puncta and such pits was
observed. In some cases, pre-existing APPL1 puncta
transiently approached clathrin-coated pits and then(I) Interaction of clathrin heavy chain with OCRL, but not with INPP5B, as revealed by western blot of material affinity purified by GST-OCRL or
GST-INPP5B from a rat brain lysate.
Scale bars are 10 mm in (A), 2.5 mm in (B), 5 mm in (C), 5 mm in (E), and 1 mm in (G).tal Cell 13, 377–390, September 2007 ª2007 Elsevier Inc. 379
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OCRL in Early Steps of the Endocytic PathwayFigure 2. The Rab5 Effector Protein APPL1 Interacts, and Colocalizes with, OCRL and INPP5B
(A) A 90 kDa protein binds OCRL and INPP5B in pull-down experiments. GST and GST fusion proteins of the COOH-terminal regions of OCRL and
INPP5B were incubated with rat brain lysate, and bound proteins were analyzed by SDS-PAGE, followed by Coomassie blue staining.
(B) Anti-APPL1 western blot of the samples shown in (A) as well as bound proteins from pull-downs in which GST fusions of full-length INPP5B and
OCRL were used as baits.
(C) The interaction between OCRL/INPP5B and APPL1 is direct. His-tagged recombinant APPL1 was incubated with the indicated GST fusion pro-
teins, and bound proteins were analyzed by western blot.
(D) OCRL and INPP5B interact with APPL1, but not with APPL2, as shown by GST pull-downs from transfected cells, followed by western blot.
(E) Coprecipitation of OCRL with APPL1 from extracts of transfected Cos-7 cells. Western blots of the starting lysate and of the immunoprecipitates
are shown.
(F) Epifluorescence images demonstrating that APPL1 colocalizes with OCRL and INPP5B on endosomes in transfected Cos-7 cells.
(G–I) TIRF microscopy sequential images (12 s intervals) of spots positive for RFP-clathrin, EGF-OCRL, and EGFP- or RFP-APPL1 at the cell surface.
Scale bars are 2.5 mm in (F) and 1 mm in (G)–(I).moved away (Figure 2G). Of note, endosomes were re-
cently shown to transiently approach sites of endocytic
vesicle formation in yeast (Toshima et al., 2006). In many
other cases, APPL1-positive puncta appeared at the loca-
tion at which a clathrin-coated pit had just disappeared380 Developmental Cell 13, 377–390, September 2007 ª2007 E(Figure 2H) and, as often seen for OCRL (see Figure 1G),
moved away from these sites. These spots are likely to
represent an association of APPL1 with OCRL on newly
formed endocytic vesicles, because APPL1 fluorescence
was often preceded by the appearance of OCRLlsevier Inc.
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OCRL in Early Steps of the Endocytic PathwayFigure 3. OCRL and APPL1 Are Compo-
nents of a Protein Network Implicated
in Receptor Trafficking and Signaling
(A) Schematic drawing indicating direct and
indirect interactions of OCRL described in this
study or reported in the literature. The PDZ do-
main of GIPC binds the COOH terminus of both
the TrkA receptor and megalin. The PTB do-
main of APPL1 also binds the cytoplasmic do-
main of TrkA. A direct interaction of this PTB
domain with megalin remains hypothetical.
(B) GST pull-downs of a rat brain lysate on GST
or GST fusions of the COOH-terminal region of
OCRL (top) or of the cytoplasmic domain of
megalin (bottom). The western blots demon-
strate the presence of both APPL1 and GIPC
in both pull-downs.
(C) Protein network involving OCRL and APPL1
and potentially relevant to the kidney and brain
defects observed in Lowe syndrome. Loss-of-
function mutations of proteins indicated in red
lead to renal proximal tubule reabsorption
defects either in human (OCRL) or in mouse
(megalin, GIPC, and Dab2) (see text).
(D) Presence of APPL1 in both rat brain and
kidney lysates (western blot).
(E) Immunofluorescence of cross-sectioned
(cryostat sections) mouse kidney proximal
tubules showing enrichment of APPL1 at the
apical region of the epithelium, where it coloc-
alizes with GIPC, myosin VI, and megalin, and
also, partially, with g-adaptin. The scale bars
are 10 mm.fluorescence (Figure 2I; Movie S3). The dynamic pattern of
EGFP-Rab5 fluorescence, as revealed by TIRF, was very
similar to that of APPL1 (not shown).
A Protein Network Implicated in Receptor
Endocytosis and Recycling
APPL1 is an adaptor/signaling protein that binds the
membrane (via BAR and PH domains); several transmem-
brane receptors, including the nerve growth factor recep-
tor TrkA (via a PTB domain); and the oligomeric endocytic
adaptor protein GIPC (via a COOH-terminal PDZ-binding
motif) (Figure 3A) (Lin et al., 2006; Liu et al., 2002; Mao
et al., 2006; Varsano et al., 2006). GIPC also binds TrkA
(Figure 3A) and, together with APPL1, participates in the
regulation of endocytic trafficking of this receptor (LinDevelopmenet al., 2006; Varsano et al., 2006). We found that GIPC
was present together with APPL1 in the material that
was affinity purified from rat brain lysate on a GST fusion
of the COOH-terminal region of OCRL (Figure 3B, top),
indicating that a complex of these proteins may occur
in vivo. It is therefore possible that the neurological and
cognitive manifestations of Lowe syndrome may be
mediated, at least in part, by an effect of impaired OCRL
function on TrkA signaling.
The interaction of APPL1 with GIPC is also of special
significance in the context of the kidney defects observed
in patients with OCRL mutations because GIPC directly
binds megalin (Lou et al., 2002) (Figure 3A). Interestingly,
not only GIPC, but also APPL1, was recovered in a pull-
down from a rat brain extract with a GST fusion of thetal Cell 13, 377–390, September 2007 ª2007 Elsevier Inc. 381
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OCRL in Early Steps of the Endocytic Pathwaycytoplasmic domain of megalin (Figure 3B, bottom). These
results point to a molecular network that in the kidney
links OCRL to the reabsorption machinery of the proximal
tubule (Figure 3C). Indeed, GIPC knockout mice, as well
as mice defective in megalin or in another megalin adap-
tor, Dab2, exhibit low-molecular weight proteinuria (Le-
heste et al., 1999; Naccache et al., 2006; Nagai et al.,
2005). To provide evidence for a role of APPL1 in this net-
work, we investigated the expression and localization of
APPL1 in the kidney.
Both OCRL (Janne et al., 1998) and APPL1 (Figure 3D)
are expressed in the kidney. APPL1 immunoreactivity in
kidney proximal tubules appeared as an apical band of
tightly apposed puncta just below the brush border
(Figure 3E). This is the region in which endocytic and recy-
cling vesicles implicated in reabsorption from the primary
urine are localized. Accordingly, APPL1 immunoreactivity
strikingly overlapped with megalin and with other endo-
cytic proteins concentrated in this region, including
clathrin (Rodman et al., 1984), GIPC (Lou et al., 2002),
Dab2 (Nagai et al., 2005), Rab5, and myosin VI, a GIPC
and Dab2 interactor and a marker of clathrin-coated and
newly uncoated vesicles (Naccache et al., 2006; Nagai
et al., 2005) (Figure 3E and data not shown). Available
antibodies did not allow for the reliable detection of OCRL
in kidney proximal tubules by immunocytochemistry.
However, the localization of the major binding partners
of OCRL at the apical pole of these cells (APPL1, Rab5,
clathrin) strongly suggests localization of OCRL as well
in this region. It is of interest that even the AP-1 clathrin
adaptor complex (as visualized by immunofluorescence
of g-adaptin), which was shown to colocalize with OCRL
in the Golgi complex area (Choudhury et al., 2005), ex-
tends into the apical region containing APPL1-positive en-
dosomes in kidney proximal tubule cells (Figure 3E). These
findings are consistent with the hypothesis that kidney
defects produced by OCRL mutations reflect abnormal
endocytic trafficking and/or signaling at the apical pole
of proximal tubule cells. Given the potential importance
of the binding of OCRL to APPL1 in disease, a molecular
analysis of this interaction was performed.
A Short Peptide in APPL1 Mediates Binding
to OCRL and INPP5B
Interaction surfaces between APPL1 and OCRL/INPP5B
were analyzed by using protein fragments as baits in
GST pull-down assays from brain lysates. APPL1 deletion
constructs defined the minimal binding site as an 11-mer
peptide within the region comprised between the PH
and the PTB domain (Figures 4A and 4B). Mutation to ala-
nine of the phenylalanine at the +2 position of this peptide
(F404A) completely abolished binding (Figure 4B). Inter-
estingly, this short sequence is highly conserved across
species but is not present in APPL2 (Figure 4A), thus ex-
plaining the selective binding of OCRL and INPP5B to
APPL1 (Figure 2D). The affinity (KD) of the interaction be-
tween the COOH-terminal region of ORCL and the 11-
mer APPL1 peptide, as measured by isothermal titration382 Developmental Cell 13, 377–390, September 2007 ª2007calorimetry (ITC), was 20 mM, while the F404A peptide
did not show any measurable binding (Figure 4C).
The 11-mer peptide of APPL1 and adjacent regions
contain a number of potential serine/threonine phosphor-
ylation sites (Figure 4A). A phosphorylation-dependent
regulation of the interaction between APPL1 and OCRL/
INPP5B would support its physiological significance.
In vitro phosphorylation of the GST 11-mer peptide with
several protein kinases revealed strong phosphorylation
by the catalytic subunit of protein kinase A (PKA), but
not other kinases (Figure 4D and data not shown). Interest-
ingly, the reabsorption rate of kidney proximal tubules is
regulated by manipulations that enhance PKA activity,
such as forskolin or parathyroid hormone (PTH) (Gekle
et al., 1997). Replacing the two serines within the 11-mer
peptide (S403 and S410) with aspartate mapped the
phosphorylation site to S410 (Figure 4D). The phospho-
mimetic S410D mutation strongly inhibited the binding of
the peptide to OCRL both in GST pull-downs (not shown)
and in coprecipitation experiments (Figure 4E). Likewise,
overexpression of PKA together with HA-OCRL and
EGFP-APPL1 in Cos-7 cells reduced the coprecipitation
of the two proteins (Figure 4F), supporting a physiological
role of this phosphorylation reaction.
Efforts to narrow down the APPL1-interacting region
within the COOH-terminal region of OCRL and INPP5B re-
vealed that both COOH-terminal and NH2-terminal trun-
cations of this protein fragment abolished binding (Fig-
ure S2). Hence, this fragment appears to function as a
folded unit that recognizes APPL1 in a module-peptide
type of interaction. To gain structural insight into the
COOH-terminal region of OCRL, X-ray crystallography
studies were performed.
Atomic Structure of the COOH-Terminal Region
of OCRL
The crystal structure of the selenomethionine-substituted
COOH-terminal region (residues 564–901) of human
OCRL (GI: 57209431) was determined by using the single
anomalous dispersion (SAD) method (Table S1). This re-
gion of OCRL is composed of an NH2-terminal module
(ASH domain, see below) (residues 564–678), represented
primarily by b strands, and a COOH-terminal RhoGAP-like
domain (residues 679–901) (Figures 5A and 5B). The two
domains are closely apposed to each other in a rigid orien-
tation determined by a number of polar and apolar interac-
tions that bury a total solvent-accessible surface area of
1056.2 A˚2. These interactions may help stabilize the struc-
ture of the ASH domain, which was not stable in solution
when expressed alone.
RhoGAP-like Domain
The RhoGAP-like domain is very similar to previously
characterized RhoGAPs (Peck et al., 2002) (Figure 5C).
When compared to p50RhoGAP, the rmsd value was
1.42 A˚ over a total of 146 residues. However, the catalytic
arginine is replaced by a glutamine (Figures S3 and S4),
and the F0 helix (Figure 5C) is missing. These differences
explain why the RhoGAP-like domain of OCRL has noElsevier Inc.
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OCRL in Early Steps of the Endocytic PathwayFigure 4. Mapping of the Binding Interfaces between APPL1 and OCRL
(A) Modular structure and interactions of APPL1. The figure also shows an alignment of the 11-mer peptide of human APPL1 with the corresponding
sequence of APPL from other species, demonstrating its evolutionary conservation. The sequence is not conserved in human APPL2. Potential phos-
phorylation sites within the 11-mer peptide are indicated by asterisks.
(B) GST pull-downs from extracts of Cos-7 cells expressing either Myc-tagged OCRL or Xpress-tagged INPP5B define an 11 amino acid (residues
403–413) stretch of human APPL1 as the minimal region necessary and sufficient for binding. Bound proteins were identified by western blot. Num-
bers indicate the amino acid boundaries of the APPL1 fragment fused to GST. The F404A mutation abolished binding.
(C) ITC analysis of the binding of the wild-type APPL1 11-mer peptide and of the F404A mutant peptide. Raw data are shown in the upper panels, and
plots of the total heat released as a function of the molar ratio of each ligand are shown in the bottom panels.
(D) GST fusions of the wild-type or mutant (S403D and S410D) minimal binding region (11-mer peptide) were incubated with the catalytic subunit of
PKA or with type II Ca2+-calmodulin-dependent kinase (CamKII) in the presence of g-32P[ATP]. Proteins were separated by SDS-PAGE, and the cor-
responding autoradiography is shown.
(E) Coimmunoprecipitation of full-length wild-type and mutant (S410D) APPL1 with OCRL.
(F) PKA overexpression impairs binding of APPL1 to OCRL in vivo. For (E) and (F), Cos-7 cells were transfected with the indicated expression con-
structs. Protein complexes were immunoprecipitated with anti-GFP antibody, and the starting lysates and the immunoprecipitates were analyzed by
western blot.detectable GAP activity against a number of G proteins
tested, including its known interactors Rac and Cdc42
([Lichter-Konecki et al., 2006] and unpublished data). A
striking characteristic of the RhoGAP-like domain of
OCRL is the presence of an extended (40 amino acids)
loop between aA0 and aA (Figures 5A and 5B). The elec-
tron density of most of this loop is visible due to the crystal
packing, which stabilizes an interaction of the loop with
adjacent molecules ‘‘in trans.’’ The loop contains the
type I clathrin-binding motif (clathrin box) 702LIDLE706 (Fig-
ures 5A and 5E; and Figure S5), which was previously
thought to lay outside of the RhoGAP-like domain. Such
a loop is subject to alternative splicing (Lowe, 2005)—Developmenexclusion or inclusion of 8 residues downstream of the
clathrin box motif that contain a predicted casein kinase
II phosphorylation site—and is shorter in INPP5B, which
lacks the clathrin box.
The insertion of the long loop after the aA0 helix has
previously blurred the definition of the boundaries of the
RhoGAP-like domain based on primary sequence. This
may explain why, in contrast to what has been described
for OCRL, no evidence for an interaction of INPP5B with
Rac or Cdc42 was reported. Indeed, when tested in pull-
down experiments from extracts of Cos-7 cells expressing
constitutively active Rac1 (Rac1V12), Cdc42 (Cdc42V12),
or Rho (RhoV12), the RhoGAP-like domains of both OCRLtal Cell 13, 377–390, September 2007 ª2007 Elsevier Inc. 383
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OCRL in Early Steps of the Endocytic PathwayFigure 5. Structure of the COOH-Terminal Region of OCRL
(A) Ribbon diagram with the ASH domain (red) and the RhoGAP-like domain (blue). Residues of the clathrin box motif are shown as sticks.
(B) Stereo view of the Ca backbone traces. Trace color was ramped from the NH2 terminus (red) to the COOH terminus (blue). Every 20 residues are
labeled and indicated with small, filled circles.
(C) (Left) RhoGAP-like domain of OCRL (blue) superimposed on the RhoGAP domain of P50RhoGAP (PDB ID: 1AM4). Bound Cdc42 is shown in gold.
(Right) Biochemical interaction of the RhoGAP-like domain of OCRL and INPP5B with Rac and Cdc42. GST pull-downs from lysates of Cos-7 cells
expressing tagged versions of Rac, Rho, or Cdc42 with GST fusions of the RhoGAP-like domain of OCRL or INPP5B. Bound proteins were analyzed
by western blot.
(D) Alignment of the ASH domain of OCRL and INPP5B with other members of the MSP/VAP domain protein family. The E585 deletion mutation found
in a patient is marked by a black triangle. Secondary structure elements are drawn above the alignment. Entrez database accession numbers are as
follows: OCRL_Hs, GI: 57209431; Inpp5_Hs, GI: 59803021; OCRL_Dr, GI: 68374521; Inpp5_Dm, GI: 54642833; Inpp5_Ce, GI: 17505597; Inpp5_Dd,
GI: 66828629; MSP_Ce, GI: 21730216; Vap-A_Rn, GI: 73535850. Hs, Homo sapiens; Dr, Danio rerio; DM, Drosophila melanogaster; CE, Caenorhab-
ditis elegans; Dd, Dictyostelium discoideum; Rn, Rattus norvegicus.and INPP5B (GI: 30231213) bound Rac and Cdc42, but
not Rho (Figure 5C). Similar to OCRL, INPP5B also inter-
acted with dominant-negative RacN17, indicating nucleo-
tide-independent binding (Figure 5C).
ASH Domain
The NH2-terminal module is comprised of two layers of
b sheets (parallel strand b1, b6, antiparallel strand b5,
and antiparallel strands b2, b4, and b3) (Figures 5A and
5B). Hydrophobic side chains from the two layers occupy
the interior of the sandwich. There was no interpretable
electron density for the tip of this module distal to the Rho-
GAP-like domain, most likely due to its flexible nature and
to the lack of crystal-packing contacts around this region.384 Developmental Cell 13, 377–390, September 2007 ª2007 EThe overall folding of this module is closely related to that
of the MSP and VAP domains, members of the family of
immunoglobulin-like b sandwiches with s-type topology
(Bork et al., 1994; Kaiser et al., 2005). This structure is in
agreement with a recent bioinformatics study that, based
on a remote primary sequence similarity, included these
regions of OCRL and INPP5B into the newly defined
ASH (ASPM, SPD2, and Hydin) domain family (Figure 5D)
(Ponting, 2006).
The VAP domain, which is found in several endoplasmic
reticulum proteins, interacts with the conserved FFAT mo-
tif, present in a family of oxysterol-binding proteins (Loe-
wen et al., 2003). A 10 residue peptide comprising the
FFAT motif binds to a groove perpendicular to the mainlsevier Inc.
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to speculate that the 11-mer peptide of APPL1 binds in
a similar fashion to the ASH domain of INPP5B and
OCRL. However, as shown above, binding of the 11-mer
peptide requires both the intact ASH and the RhoGAP-
like domains. This may be due to a role of the RhoGAP-
like domain in the stabilization of the ASH domain (see
above) or to a binding interface contributed by both do-
mains. Attempts to cocrystallize the 11-mer peptide with
the ASH-RhoGAP-like domains were unsuccessful.
APPL1 Binding and Human Mutations
Deletions of the COOH-terminal region of OCRL as well as
three distinct single amino acid changes in this region
have been associated with Lowe syndrome (Monnier
et al., 2000). The three single amino acid mutations
(DE585, I768N, A797P) were mapped on the crystal struc-
ture (Figure 6A). E585 is located in the b2 strand of the ASH
domain, and its deletion may be disruptive of the correct
structure of this domain. I768 is located in the middle of
aA1 of the RhoGAP-like domain, and its side chain points
to the hydrophobic core formed by aA, aA1, and aB. Mu-
tation of this nonpolar residue to the polar residue aspar-
agine is also likely to affect folding. A797 is located at the
end of aB, at the interface between the RhoGAP-like and
ASH domains, and is thus in a position to perhaps affect
the interaction between these two domains. ASH-Rho-
GAP-like domains harboring these mutations were tested
for APPL1 binding in GST pull-down assays. None of
these mutant proteins bound to APPL1, while binding to
Rac and clathrin was preserved (Figure 6B). Accordingly,
immunofluorescence revealed no colocalization of EGFP-
OCRL harboring these three mutations with RFP-APPL1
(Figure 6C), although APPL1 still had a punctate peripheral
distribution. These findings support the hypothesis that an
impairment of the interaction between OCRL and APPL1
may play a role in disease.
DISCUSSION
The localization and interactions of OCRL reported in this
study suggest a role of OCRL at early steps of the endo-
cytic pathway and its action, via its binding to APPL1, in
a protein network closely linked to some of the phenotypic
manifestations of Lowe syndrome and Dent disease. Our
structural studies demonstrate that the entire COOH-
terminal region of OCRL functions as a folded unit, thus
explaining why truncations of this region at either end
abolish binding to APPL1. The structure of this region re-
veals how its multiple interactions may help position the
catalytic site of the inositol 5-phosphatase module at the
membrane interface. To our knowledge, it also shows
the first structure of an ASH domain.
OCRL and the Early Endocytic Pathway
Recent studies had demonstrated localizations of OCRL
not limited to the Golgi complex area, as originally re-
ported, but also on endosomes, and functional studiesDevelopmensuggested its role in transport between endosomes and
the trans-Golgi complex (Choudhury et al., 2005; Unge-
wickell et al., 2004). We now show that OCRL is also pres-
ent at a subpopulation of endocytic clathrin-coated pits,
and that one of its important binding partners is a protein,
APPL1, implicated in signaling and sorting of cell-surface
receptors that is localized, together with OCRL, on a sub-
set of peripheral early endosomes (Miaczynska et al.,
2004). Recent studies have also implicated INPP5B in en-
dosomal function (Shin et al., 2005). Together, these find-
ings solve the apparent paradox raised by a selective con-
centration of OCRL in the Golgi complex: the discrepancy
between this localization and the predominant concentra-
tion of its preferred substrates, PI(4,5)P2 and PI(3,4,5)P3
(Schmid et al., 2004) (also see Figure S6), at the plasma
membrane (Di Paolo and De Camilli, 2006; Stauffer
et al., 1998). They strongly suggest that OCRL functions
in the coupling of endocytic trafficking to PI(4,5)P2 and
PI(3,4,5)P3 dephosphorylation, as reported for INPP5B
(Shin et al., 2005) and synaptojanin (Cremona et al.,
1999). This scenario does not exclude roles of the two
phosphatases at their other intracellular locations, where
they may function to prevent ectopic or abnormal accu-
mulation of these phosphoinositides.
A Structural Model of OCRL
Our crystallographic results demonstrate the striking
structural similarity between the COOH-terminal portion
of OCRL and RhoGAP domains, in spite of the lack of a
catalytic arginine, reveal the structure of an ASH domain,
and support the assignment of this domain to the MSP/
VAP domain superfamily (Ponting, 2006). Since both
OCRL and INPP5B metabolize inositol phospholipids, it
is of interest to note that mutations of the VAP domain pro-
tein Scs2 in Saccharomyces cerevisiae confer inositol
auxotrophy (Kagiwada et al., 1998), and, more generally,
that VAP domains bind lipid-metabolizing enzymes (Loe-
wen et al., 2003).
The structure of the ASH-RhoGAP-like domains of
OCRL, together with the predicted structure of the inositol
5-phosphatase domain (based on the 5-phosphatase
domain of Schizosaccharomyces pombe synaptojanin
[Tsujishita et al., 2001]) allows for modeling of OCRL and
INPP5B at the membrane interface (Figure 7). The
COOH terminus of INPP5B is farnesylated (Jefferson
and Majerus, 1995) and is thus expected to be adjacent
to the membrane. Although the COOH-terminal region of
OCRL lacks a motif predictive of farnesylation, its strong
overall similarity to INPP5B suggests a similar localization/
orientation relative to the membrane. Such an orientation
is compatible with an interaction of the RhoGAP-like do-
mains of both phosphatases with membrane-bound,
small G proteins, which may thus provide an indirect an-
chor at the membrane for OCRL and a second anchor
for INPP5B. The rigid angle between the ASH and Rho-
GAP-like domains may guide the ASH domain away
from the bilayer and make it dock to the inositol 5-phos-
phatase module in a way that allows for the juxtaposition
of the catalytic site to the membrane. Three residuestal Cell 13, 377–390, September 2007 ª2007 Elsevier Inc. 385
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OCRL in Early Steps of the Endocytic PathwayFigure 6. OCRL Point Mutations of Lowe Syndrome Patients Abolish the Interaction with APPL1
(A) Close-up view of the local structural environment of three single amino acid patient mutations in the COOH-terminal region of OCRL.
(B) GST pull-downs from extracts of rat brain (APPL1, clathrin) or transfected Cos-7 cells (Myc-RacV12) on wild-type and mutant fusion proteins,
demonstrating that each of the three mutations abolishes binding to APPL1, but not to clathrin or Rac (Myc-RacV12). Bound proteins were detected
by western blot.
(C) Two-color fluorescence of cells expressing RFP-APPL1 and EGFP-OCRL (wild-type or mutant). Wild-type OCRL is localized on spots throughout
the cell. The more peripheral spots (arrowheads), but not all spots (arrows), colocalize with APPL1. Each of three patient mutations abolishes the co-
localization with APPL1, although APPL1-positive spots at the periphery persist. Note that, at least for the D585 mutation, OCRL still has a punctate
subcellular distribution. The scale bar is 3 mm.whose mutations abolish Rab5 binding (D555E, S564P,
G664D [Hyvola et al., 2006]) form a cluster (Figure 7;
oval, solid line) that is separated from the bilayer by a dis-
tance that can accommodate membrane-bound Rab5.386 Developmental Cell 13, 377–390, September 2007 ª2007 EThe model also shows how the clathrin box motif projects
away from other domains, thus being accessible to the
foot of clathrin triskelia, i.e., the clathrin heavy-chain mod-
ule that binds clathrin boxes (ter Haar et al., 2000).lsevier Inc.
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OCRL in Early Steps of the Endocytic PathwayFigure 7. Structural Model of the Inter-
action of OCRL and INPP5B with the
Membrane
The ASH-RhoGAP-like domains of OCRL were
docked to the structure of the inositol 5-phos-
phastase domain from S. pombe determined
by Hurley and coworkers (Tsujishita et al.,
2001). The NH2-terminal domain of OCRL,
whose structure remains unknown, is not in-
cluded. OCRL and INPP5B form an arc that is
anchored to the membrane via the catalytic
site of the inositol 5-phosphatase domain
(shown here in a complex with the head group
of a phosphoinositide) (PDB ID: 1I9Z) and the
COOH-terminal region of the RhoGAP-like do-
main, which, in INPP5B, is farnesylated. Three
mutations that abolish Rab5 binding are lo-
cated within a small region (oval, solid line),
whose distance from the bilayer can accom-
modate a small GTPase such as Rab5. Rac
or Cdc42 could also be accommodated next
to the RhoGAP-like domain. The precise bind-
ing interface for APPL1 (oval, broken line) re-
mains to be defined. The clathrin-binding site
protrudes from the structure.OCRL, Lowe Syndrome, and Dent Disease
The identification of APPL1 as an interactor of OCRL and
INPP5B places these two phosphatases in protein net-
works that are likely to be relevant for the functional de-
fects characteristic of Lowe syndrome and Dent disease
(Figure 3C). APPL1 is an adaptor/signaling protein whose
PTB domain directly binds cell-surface receptors, includ-
ing DCC (deleted in colon cancer), adiponectin, FSH re-
ceptor, and TrkA (Lin et al., 2006; Liu et al., 2002; Mao
et al., 2006; Nechamen et al., 2004). Its COOH terminus
binds GIPC (Lin et al., 2006), an oligomeric adaptor that
provides an additional link to a variety of receptors, includ-
ing TrkA (Lou et al., 2001) and megalin (Lou et al., 2002),
a scavenger receptor in the kidney proximal tubule.
GIPC also binds myosin VI, a molecular motor implicated
in the motility of endocytic vesicles, such as the vesicles
that recycle megalin in the kidney (Naccache et al.,
2006). Mice lacking expression of megalin, GIPC, or
Dab2, another endocytic adaptor for megalin, display uri-
nary defects similar to those observed in Lowe syndrome
and Dent disease patients (Leheste et al., 1999; Naccache
et al., 2006; Nagai et al., 2003). In kidney proximal tubule
cells, APPL1 is present together with these proteins in
the apical region, where endocytic vesicles that internalize
and recycle cell-surface proteins implicated in reabsorp-
tion are also localized. Furthermore, an interaction of
OCRL with GIPC, most likely mediated by APPL1, could
be detected by pull-down experiments.
Thus, given the importance of DCC and TrkA signaling
in the brain and of megalin function in the kidney (megalin
also has important functions in the brain), the mental retar-
dation and kidney reabsorption defects observed in Lowe
syndrome may reflect a role of OCRL in the regulation of
receptor trafficking via the APPL1/GIPC complex. The de-
creased shedding of megalin in the urine of patients withDevelopmenOCRL mutations provides genetic evidence for this hy-
pothesis (Norden et al., 2002). Importantly, the interaction
with APPL1 is the only one shown to be selectively disrup-
ted by all three published disease-relevant mutations
in the COOH-terminal region of OCRL. Changes in the
phosphoinositide composition of endosomal membranes
resulting from the absence of OCRL, such as an ectopic
accumulation of PI(4,5) 2 and PI(3,4,5)P3, may impact sort-
ing of receptors in multiple ways, including retrograde
trafficking to the Golgi complex, as reported (Choudhury
et al., 2005; Ungewickell et al., 2004).
In parallel to effects on trafficking, OCRL mutations may
also produce defects in signaling pathways downstream
of PI(4,5)P2 and/or PI(3,4,5)P3. Activation of TrkA results
in the generation of PI(3,4,5)P3 and subsequent Akt activa-
tion (Kaplan and Miller, 2000). Megalin was reported to
bind Akt (Caruso-Neves et al., 2006). It is therefore of inter-
est that OCRL dephosphorylates PI(3,4,5)P3 (Schmid
et al., 2004) (Figure S6) and that APPL1 interacts with
AKT2 (Mitsuuchi et al., 1999). The localization of OCRL
and INPP5B on endocytic membranes and binding of
these proteins to APPL1 may affect the duration and local-
ization of AKT signaling on such membranes as their re-
ceptor cargo progresses along the endocytic pathway. It
is also possible that the activity of OCRL in kidney cells
may be needed to prevent accumulation of PI(3,4,5)P3 at
the apical pole, given the recent finding that PI(3,4,5)P3
is excluded from the apical surface (Martin-Belmonte
et al., 2007). Finally, molecular defects in OCRL may
affect, directly or indirectly, the nuclear-cytoplasmic shut-
tling of APPL1 (Miaczynska et al., 2004), and thus the
nuclear actions of this protein.
Collectively, our findings provide a context in which to
interpret some of the defects observed in patients with
OCRL mutations and provide important information thattal Cell 13, 377–390, September 2007 ª2007 Elsevier Inc. 387
Developmental Cell
OCRL in Early Steps of the Endocytic Pathwaycan be used toward the formulation of testable hypothe-
ses concerning the physiological function of OCRL and
its role in disease.
EXPERIMENTAL PROCEDURES
Antibodies, Plasmids, and Critical Reagents
Rabbit polyclonal antibodies were raised against His-tagged fusion
proteins of mouse OCRL (amino acids 1–220) and INPP5B (amino
acids 1–256) or against a synthetic peptide (CINKPDEESYCKQWL
TARPSKG) of INPP5B. The rabbit polyclonal anti-megalin antibody
(anti-MC-220) was described (Zou et al., 2004). Antibodies purchased
from commercial sources are listed in the Supplemental Data. Other
antibodies were from our laboratory. Full-length cDNAs for mouse
INPP5B, human OCRL, human APPL1 and APPL2, and mouse Rab5
were amplified by PCR from brain cDNA libraries (Clontech) and
were subcloned into the expression vectors pEGFP-C1 or pcDNA3.1
harboring either a Myc tag or an RFP-NH2-terminal tag. Phospho-
inositides were purchased from Echelon Research Laboratories. The
following reagents were kind gifts: Myc-Rab5Q79L in pcDNA3 from
Hong Chen in our laboratory; EGFP-Rab9 from Suzane Pfeffer (Stan-
ford University); RFP-clathrin light chain from James Keen (Thomas
Jefferson University); HA-tagged protein kinase A (catalytic subunit)
from Susan Taylor (University of California, San Diego); and CaMKII
from Angus Nairn (Yale University).
Purified Proteins
Full-length OCRL and INPP5B were generated in insect cells as GST
fusion proteins by using the bacculovirus vector pAcGHLT-A (Phar-
Mingen). cDNA contructs encoding fragments of OCRL, INPP5B,
APPL1, and megalin were subcloned into the pGEX-6P-1 expression
vector (Amersham) to obtain GST fusion proteins or the pET30 vector
(QIAGEN) to obtain His-tagged proteins. Fusion proteins were purified
on glutathione Sepharose or nickel beads according to standard
protocols.
Pull-Down and Coimmunoprecipitation Experiments
Extracts from adult rat tissues (lysates) were prepared by homogeniza-
tion in lysis buffer (PBS, 0.5% Triton [v/v], protease inhibitor mixture
[Roche]), followed by ultracentrifugation (100,000 3g, 45 min, 4C) to
remove insoluble material. GST pull-downs from the extracts were per-
formed by following standard protocols. For immunoprecipitation, cell
extracts (2–3 mg) were first incubated with antibodies (3 hr) and then
with protein A-Sepharose beads (Amersham Biosciences) for 2 hr at
4C, followed by centrifugation and several washes in lysis buffer.
Proteins recovered on beads in either procedure were eluted with
SDS sample buffer and separated by SDS-PAGE.
Cell Culture, Transfection, and Microscopy
Cos-7 cells or HEK293 cells (ATCC, Rockville, MD) were cultured at
37C and 10% CO2 in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum. Transfections were carried out
with Fugene (Roche) or Lipofectamine 2000 (Life Technologies), and
cells were observed after 16–24 hr. Still fluorescence microscopy
was performed by following standard procedures.
Total internal reflection microscopy was performed as described by
Zoncu et al. (2007). For details, see the Supplemental Data.
Isothermal Titration Calorimetry
Isothermal titration calorimetry (ITC) measurements were performed
as described (Lee et al., 2005) by using a Microcal VP-ITC isothermal
titration calorimeter equipped with a PC running VPViewer software
(http://microcal.com). Dissociation constant values were obtained
with Origin software. See the Supplemental Data for details.388 Developmental Cell 13, 377–390, September 2007 ª2007In Vitro Phosphorylation
GST fusions (each 2.5–5 mg) were mixed with purified kinases (150–
200 ng) (a kind gift of Dr. Angus Nairn, Yale University) in the presence
of 10 mCi g-[32P]ATP (1 Ci = 37 GBq) and 100 mM ATP for 1 hr at 32C.
Protein kinase A phosphorylation reactions were performed in buffer
A (50 mM HEPES [pH 7.4], 10 mM MgCl2, 1 mM EGTA, and 1 mM
b-mercaptoethanol). Reactions were quenched by the addition of
SDS-PAGE sample buffer, and samples were analyzed by SDS-
PAGE and autoradiography.
Protein Crystallization, Data Collection, and Structure
Determination
A selenomethionine-substituted GST fusion of the COOH-terminal
region of human OCRL1 (residues 564–901) was prepared and crystal-
lized as described in the Supplemental Experimental Procedures.
X-ray data were acquired at the Advanced Photon Source NE-CAT
24ID beamline (Argonne, IL). All diffraction data were processed with
HKL 2000 (Otwinowski and Minor, 1997), and the structure of the crys-
tal was determined by single anomalous dispersion (SAD) phasing with
CNS (Brunger et al., 1998). The resulting experimental electron density
map was displayed, and an initial model was built with Xtalview
(McRee, 1999). The structure was refined against the 2.4 A˚ refinement
data (Table S1) by simulated annealing, conjugate gradient minimiza-
tion, and restrained isotropic B factor refinement. The final model has
R and Rfree values of 24.7% and 28.8%, respectively, and has no res-
idues in the disallowed region of the Ramachandran plot. Other details
of structure determination are given in the Supplemental Experimental
Procedures.
Miscellaneous Procedures
SDS-PAGE and western blot were performed by standard procedures.
The APPL1 band was identified by LC MS/MS at the Keck Research
Facility at Yale University. The malachite green assay was performed
as described (Maehama et al., 2000), by using 20–50 ng GST-OCRL
or GST-INPP5B purified from baculovirus-infected SF9 cells. The Rho-
GAP assay was performed by using the Biochem kit (Cytoskeleton).
Mutations were introduced into plasmids by using the QuikChange
Site-Directed Mutagenesis Kit (Stratagene).
Supplemental Data
Supplemental Data include detailed Supplemental Experimental Pro-
cedures, six figures, a crystallographic table, and three movies and
are available at http://www.developmentalcell.com/cgi/content/full/
13/3/377/DC1/.
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